2269 Stock Overview
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$23.15 |
| 52 Week High | HK$29.15 |
| 52 Week Low | HK$10.14 |
| Beta | 0.56 |
| 1 Month Change | 16.10% |
| 3 Month Change | 7.93% |
| 1 Year Change | 59.66% |
| 3 Year Change | -57.37% |
| 5 Year Change | -48.82% |
| Change since IPO | 145.84% |
Recent News & Updates
WuXi Biologics (Cayman) Inc.'s (HKG:2269) 27% Jump Shows Its Popularity With Investors
May 08
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
May 07Recent updates
WuXi Biologics (Cayman) Inc.'s (HKG:2269) 27% Jump Shows Its Popularity With Investors
May 08WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
May 07WuXi Biologics (Cayman) Inc. (HKG:2269) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Mar 16
Follow The Molecule Strategy And Global Expansion Will Secure Future Opportunities
Feb 09 Robust pipeline growth with new projects and North American focus drive future revenue and stabilize amidst geopolitical tensions.WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark
Jan 25Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Dec 17After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Shareholder Returns
| 2269 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -0.4% | -4.7% | 3.4% |
| 1Y | 59.7% | 53.5% | 13.0% |
Return vs Industry: 2269 exceeded the Hong Kong Life Sciences industry which returned 53.5% over the past year.
Return vs Market: 2269 exceeded the Hong Kong Market which returned 13% over the past year.
Price Volatility
| 2269 volatility | |
|---|---|
| 2269 Average Weekly Movement | 12.1% |
| Life Sciences Industry Average Movement | 10.8% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2269's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2269's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12,575 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 2269 fundamental statistics | |
|---|---|
| Market cap | HK$94.03b |
| Earnings (TTM) | HK$3.63b |
| Revenue (TTM) | HK$20.21b |
25.9x
P/E Ratio4.7x
P/S RatioIs 2269 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2269 income statement (TTM) | |
|---|---|
| Revenue | CN¥18.68b |
| Cost of Revenue | CN¥11.02b |
| Gross Profit | CN¥7.65b |
| Other Expenses | CN¥4.29b |
| Earnings | CN¥3.36b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.83 |
| Gross Margin | 40.97% |
| Net Profit Margin | 17.97% |
| Debt/Equity Ratio | 5.8% |
How did 2269 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 17:44 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi Biologics (Cayman) Inc. is covered by 47 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Jian Xiong Lim | CFRA Equity Research |